HepaRegeniX Appoints Dr. Martin Bonde as New Chair of the Board

HepaRegeniX GmbH, a clinical-stage company focused on liver disease therapies, has announced Dr. Martin Bonde as its new Chair of the Board. This appointment follows a recent €15 million financing round to support Phase II clinical trials of their novel liver regeneration therapy. Dr. Bonde replaces Elias Papatheodorou, now the CEO and Managing Director. His extensive experience spans various companies within the biotech sector, enhancing HepaRegeniX's strategic initiatives.

HepaRegeniX is developing HRX-215, a promising regenerative treatment targeting the MKK4 pathway. Their past Phase I trial results in the journal Cell were favorable. Upcoming efforts include a Phase Ib study in the US and an international Phase IIa study.